Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Digoxin 0.25mg Tablets in Healthy Chinese Subjects
NCT06546215Phase 1Completed
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of digoxin in heart failure (HF) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Plasma Digoxin Concentration (Fasted) at 144 hours and Plasma Digoxin Concentration (Fed) at 144 hours. Started Jul 2020; status: completed.
02
Drugs
digoxin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06546215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546215.